SEC Form 4

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres Price Ben Gil		on*		ssuer Name and Ticker trepta Therapeut						ationship of Reportin (all applicable) Director	g Person(s) to Is 10% C		
(Last) 215 FIRST STR	(First) EET, SUITE 7	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/04/2013						Officer (give title below)	Other below	(specify)	
(Street) CAMBRIDGE (City)	MA (State)	02412 (Zip)	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
Date			2. Transaction Date (Month/Day/Ye	Execution Date,	3. Transaction Code (Instr. 8)		4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Common Stock ⁽¹⁾ 06/04				.3	A		1,000(2)	A	\$ <mark>0</mark>	34,830	D		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exercis Expiration Dat (Month/Day/Ye	e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	c		Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to buy)	\$ 34.92	06/04/2013		А		20,000		06/04/2014 ⁽³⁾	06/04/2023	Common Stock ⁽¹⁾	20,000	\$0	20,000	D	

Explanation of Responses:

1. On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.

2. Grant of restricted stock, which shall vest in full on the anniversary date of the grant.

3. This option will vest at a rate of 25% annually over four years beginning on the first anniversary of the date of grant.

By: David Tyronne Howton 06/06/2013 For: Ben Gil Price

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date